Notice2022-08050
Advisory Committee on Immunization Practices (ACIP)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 14, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 72 (Thursday, April 14, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 72 (Thursday, April 14, 2022)]
[Notices]
[Page 22210]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-08050]
[[Page 22210]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0051]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment.
DATES: The meeting will be held on April 20, 2022, from 11:00 a.m. to
4:00 p.m., EDT (date and times subject to change). The meeting will be
webcast live via the World Wide Web. Written comments must be received
on or before April 27, 2022.
ADDRESSES: You may submit comments identified by Docket No. CDC-2022-
0051 by either of the following methods:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments.
<bullet> Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, Georgia 30329-4027, Attn: April 20,
2022, ACIP Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the <a href="https://www.regulations.gov">https://www.regulations.gov</a> suitability policy will be posted
without change to <a href="https://www.regulations.gov">https://www.regulations.gov</a>, including any personal
information provided. For access to the docket to read background
documents or comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a>. Do
not submit comments by email. CDC does not accept comments by email.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, Georgia 30329-4027; Telephone:
(404) 639-8367; Email: <a href="/cdn-cgi/l/email-protection#84c5c7cdd4c4e7e0e7aae3ebf2"><span class="__cf_email__" data-cfemail="8ccdcfc5dcccefe8efa2ebe3fa">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less
than 15 calendar days' notice is being given for this meeting due to
the exceptional circumstances of the COVID-19 pandemic and rapidly
evolving COVID-19 vaccine development and regulatory processes. The
Secretary of Health and Human Services has determined that COVID-19 is
a Public Health Emergency. A notice of this ACIP meeting has also been
posted on CDC's ACIP website at <a href="http://www.cdc.gov/vaccines/acip/index.html">http://www.cdc.gov/vaccines/acip/index.html</a>. In addition, CDC has sent notice of this ACIP meeting by
email to those who subscribe to receive email updates about ACIP.
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children program, along with
schedules regarding dosing interval, dosage, and contraindications to
administration of vaccines. Further, under provisions of the Affordable
Care Act, section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been approved by the CDC Director
and appear on CDC immunization schedules must be covered by applicable
health plans.
Matters to be Considered: The agenda will include discussions on
COVID-19 vaccine booster doses. A recommendation vote(s) is scheduled.
Agenda items are subject to change as priorities dictate. For more
information on the meeting agenda, visit <a href="https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html">https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html</a>.
The meeting will be webcast live via the World Wide Web; for more
information on ACIP, please visit <a href="http://www.cdc.gov/vaccines/acip/index.html">http://www.cdc.gov/vaccines/acip/index.html</a>.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: Written comments must be received on or
before April 27, 2022.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the April 20, 2022, ACIP meeting must submit
a request at <a href="http://www.cdc.gov/vaccines/acip/meetings/">http://www.cdc.gov/vaccines/acip/meetings/</a> no later than
11:59 p.m., EDT, April 18, 2022, according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by 12:00 p.m., EDT, April 19, 2022. To accommodate the
significant interest in participation in the oral public comment
session of ACIP meetings, each speaker will be limited to three
minutes, and each speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-08050 Filed 4-12-22; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 14, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.